NDC product
Mucus Relief Congestion and Headache Maximum Strength
NDC 55910-757 · Dolgencorp, Inc. (DOLLAR GENERAL & REXALL)
Key facts
| Product NDC | 55910-757 |
|---|---|
| Proprietary name | Mucus Relief Congestion and Headache |
| Nonproprietary name | Acetaminophen, Guaifenesin, Phenylephrine HCL |
| Substances | ACETAMINOPHEN, GUAIFENESIN, PHENYLEPHRINE HYDROCHLORIDE |
| Dosage form | LIQUID |
| Route | ORAL |
| Labeler | Dolgencorp, Inc. (DOLLAR GENERAL & REXALL) |
| Product type | HUMAN OTC DRUG |
| Marketing category | OTC MONOGRAPH DRUG |
| Application number | M012 |
| Pharmacologic classes | Adrenergic alpha1-Agonists [MoA], Decreased Respiratory Secretion Viscosity [PE], Expectorant [EPC], Increased Respiratory Secretions [PE], alpha-1 Adrenergic Agonist [EPC] |
| Marketing start | Jun 1, 2019 |
| Marketing end | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory